TABLE 2.
Characteristics of patients
| Parameter | Value(s) |
|---|---|
| Patients | |
| Total, n | 173 |
| Age in yr, median (range) | 54.5 (25–65) |
| Female, n (%) | 72 (41.6) |
| Male, n (%) | 101 (58.4) |
| Pharyngeal swabs (no.) | 945 |
| Underlying disease, n (%) | |
| Acute myeloid leukemia | 51 (29.5) |
| Acute lymphoid leukemia | 9 (5.2) |
| Lymphoma | 58 (33.5) |
| Myeloma | 44 (25.5) |
| Chronic lymphatic leukemia | 3 (1.7) |
| Myelofibrosis | 2 (1.1) |
| Chronic myeloid leukemia | 1 (0.6) |
| Aplastic anemia | 1 (0.6) |
| Others | 4 (2.3) |
| Disease status, n (%) | |
| At diagnosis | 59 (34.1) |
| Complete remission | 63 (36.4) |
| Partial remission | 19 (11) |
| Refractory/relapse | 14 (8.1) |
| Progression | 18 (10.4) |
| Treatment, n (%) | |
| No. of cycles | 424 |
| Myeloablative chemotherapy | 201 (47.4) |
| Reduced intensity chemotherapy | 67 (15.8) |
| Others (i.e., monoclonal antibodies, protease inhibitors, and immunomodulatory drugs) | 156 (36.8) |
| Cycles of steroid therapy | |
| No. of cycles | 295 (69.6) |
| Duration, >7 days | 94 (31.9) |
| Neutropenia (therapy related), n (%) | |
| Severe (<500 neutrophils/μl) | 213 (50.2) |
| Duration, >10 days | 135 (63.4) |
| Antibiotics, no. (%) | |
| Total administered | 458 |
| Prophylaxisa | 105 (22.9) |
| Therapy | 353 (77.1) |
| Broad-spectrum antibiotics (i.e., piperacillin-tazobactam or ceftazidime ± aminoglycoside or tigecycline; carbapenem ± aminoglycoside or tigecycline) | 258 (73) |
| Narrow-spectrum antibiotics (i.e., fluorochinolones or oral penicillin but not antimicrobial combinations) | 95 (27) |
| Antifungals, no. (%) | |
| Total administered | 159 |
| Prophylaxis (fluconazole [n = 42], micafungin [n = 17], l-AmB [n = 14], itraconazole [n = 17], voriconazole [n = 3], posaconazole [n = 11], anidulafungin [n = 1]) | 105 (66) |
| Therapy (voriconazole [n = 9], l-AmB [n = 18], caspofungin [n = 10], anidulafungin [n = 3], micafungin [n = 1], posaconazole [n = 1], itraconazole [n = 2], fluconazole [n = 6], isavuconazole [n = 4]) | 54 (34) |
a
Seventy-three of 105 (69.5) are PCP prophylaxis, and 32 of 105 (30.5) are antibacterial prophylaxis.